EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSBSLG00000024606
Gene Symbol: GABRD
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSBSLG00000023471
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSBSLG00000025008
Gene Symbol: GABRG2
3 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSBSLG00000024200
Gene Symbol: GABRG3
3 Cross references
223 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSBSLG00000003514
Gene Symbol: GABRG3
3 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSBSLG00000016851
Gene Symbol: GABBR1
3 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSBSLG00000012743
Gene Symbol: GABBR1
2 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSBSLG00000015841
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b-Like

Ensembl ID : ENSBSLG00000014773
Gene Symbol: LOC114852335
3 Cross references
193 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSBSLG00000019921
Gene Symbol: GLP2R
2 Cross references
204 Possible Orthologues:

Glucagon Receptor-Like

Ensembl ID : ENSBSLG00000019284
Gene Symbol: LOC114845719
2 Cross references
203 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSBSLG00000020446
Gene Symbol: LOC114864127
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).